Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Low-Dose statin shows promise for korean heart patients

NCT ID NCT03903029

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a low dose (10 mg) of the statin drug rosuvastatin in 242 Korean adults with high cholesterol or heart disease risk. The goal was to see how much it lowered 'bad' LDL cholesterol after 8 weeks. Results help guide cholesterol treatment in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

242 people

The number who actually took part.

Started

Oct 2014

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Four statin benefit groups per 2013 ACC/AHA guideline in Korean

Ages

21 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. subjects with prior history of clinical ASCVD 2. subjects with primary elevation of LDL cholesterol ≥190 mg/dL 3. subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL 4. subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and with estimated 10-year ASCVD risk ≥7.5%. Exclusion Criteria: 1. history of significant statin-induced rhabdomyolysis or myopathy 2. history of a significant hypersensitivity reaction to rosuvastatin 3. uncontrolled diabetes mellitus (HbA1c \>9%) 4. uncontrolled hypertension (systolic blood pressure \>190 mmHg or diastolic blood pressure \>100 mmHg) 5. current active liver disease (alanine aminotransferase and/or aspartate aminotransferase \>2 times the upper limit of normal) 6. chronic kidney disease (serum creatinine clearance \<30 ml/min) 7. creatine kinase levels \>3 times the upper limit of normal 8. use of prohibited concomitant therapies 9. history of malignancy within the last 5 years 10. women who were pregnant, breast-feeding or of childbearing potential without contraception 11. subjects who would take any medication for purposes other than this trial within 30 days after taking this study's medication.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemias

More trials for these conditions

Other studies related to the condition(s) this trial covers.